isogranulatimide   Click here for help

GtoPdb Ligand ID: 5991

Synonyms: IZA | pyridone 6
Compound class: Synthetic organic
Comment: Isogranulatimide inhibits the enzymatic activity of Chk1 and GSK-3β tyrosine kinases [5-6]. It is an ATP-competitive inhibitor with potent and reversible activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 0
Topological polar surface area 83.02
Molecular weight 276.06
XLogP 3.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=c1[nH]c(=O)c2c1c1c3ccccc3[nH]c1n1c2cnc1
Isomeric SMILES O=c1[nH]c(=O)c2c1c1c3ccccc3[nH]c1n1c2cnc1
InChI InChI=1S/C15H8N4O2/c20-14-11-9-5-16-6-19(9)13-10(12(11)15(21)18-14)7-3-1-2-4-8(7)17-13/h1-6,17H,(H,18,20,21)
InChI Key WXUJAQBSBZLVEV-UHFFFAOYSA-N
References
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]
2. Conchon E, Anizon F, Aboab B, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M. (2008)
Synthesis, checkpoint kinase 1 inhibitory properties and in vitro antiproliferative activities of new pyrrolocarbazoles.
Bioorg Med Chem, 16 (8): 4419-30. [PMID:18321713]
3. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. (2007)
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Proc Natl Acad Sci USA, 104 (51): 20523-8. [PMID:18077363]
4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem J, 451 (2): 313-28. [PMID:23398362]
5. Jiang X, Zhao B, Britton R, Lim LY, Leong D, Sanghera JS, Zhou BB, Piers E, Andersen RJ, Roberge M. (2004)
Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.
Mol Cancer Ther, 3 (10): 1221-7. [PMID:15486189]
6. Roberge M, Berlinck RG, Xu L, Anderson HJ, Lim LY, Curman D, Stringer CM, Friend SH, Davies P, Vincent I et al.. (1998)
High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide.
Cancer Res, 58 (24): 5701-6. [PMID:9865726]